Trypanosomiasis, African Clinical Trial
Official title:
Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the
last decade, and in many places the demand largely surpasses the capacities of the treatment
centers. Treatment of the disease remains unsatisfactory. All currently used drugs must be
administered parenterally, treatment is lengthy, and adverse drug reactions frequent. There
are currently no drugs which might be used as a tool to support disease control that is
easily administered and has low toxicity.
This study aims to assess the efficacy of DB289, a new, oral drug for treatment of first
stage sleeping sickness. The project will be executed in the framework of an international
consortium consisting of more than a dozen partners from academia, industry, and the
Ministries of Health of Angola and the Democratic Republic of Congo.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 2004 |
Est. primary completion date | August 2002 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: 1. The patient has early stage T. b. gambiense infection i.e. parasitologically confirmed infection in the blood or lymph and less than or equal to 5 WBC mm-3 detected in the CSF by microscopic examination 2. Patient is 16 years old or more 3. Patient has a minimal weight of 45 kilograms 4. If patient is female of child bearing potential (a women will be considered of non-child bearing potential only if she has been post menopausal for over 2 years or has had a hysterectomy), she is not lactating, she had a negative urine pregnancy test result within 24 hours prior to DB289 treatment and she agrees to use a medically proven method of contraception (abstinence from sexual intercourse acceptable) from the day of consent on until 7 Days after DB289 treatment completion (Study Day 12). 5. Patient has signed the Informed Consent. If the patient is minor, a legal guardian has signed the Informed Consent Exclusion Criteria: 1. The patient has late stage T.b. gambiense infection i.e. presence of parasite in the CSF upon microscopic examination, or a positive (titer greater than 1/4) latex / IgM test, or a positive latex / T.b.g. 2. Active clinically relevant medical conditions that in the Investigator opinion may jeopardize subject safety or interfere with participation in the study, including but not limited to: significant liver diseases, chronic pulmonary diseases, significant cardiovascular diseases or significant ECG anomaly such as elongated QTc (corrected) interval above 430 msec for men or above 450 msec for women, diabetes, thyroid diseases, gout, infection including known HIV infection, CNS trauma or seizure disorders. 3. Clinically significant abnormal laboratory value at screening including: - Prothrombin Time > 1.25 times upper limit of normal (ULN) - Liver enzyme AST and ALT > 2 times ULN - Total bilirubin > 1.5 times ULN - Serum Creatinine > 1.5 times ULN 4. Traumatic lumbar puncture (i.e. red blood cells visible in CSF) 5. Coma Score of less than 9 on the Glasgow Coma Scale (Appendix 8) 6. Withdrawal of consent at any time during the study 7. Any condition which compromises ability to communicate with the investigator as required for the completion of this study. 8. The subject has been previously treated for African Trypanosomiasis. 9. The subject has been previously enrolled in the study. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Angola | Laboratory of Reference and Investigation, Viana, ICCT | Bairro Ingombota | Luanda |
Congo | Programme National de Lutte contre la Trypanosomiase | Kinshasa | Gombe |
Lead Sponsor | Collaborator |
---|---|
Immtech Pharmaceuticals, Inc | Bill and Melinda Gates Foundation |
Angola, Congo,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy endpoint is the parasitological cure 24 hours after completion of treatment. | Day 7 | No | |
Primary | The primary outcome measure for safety analysis will be the rate of occurrence of Grade 3 or higher adverse events during the observation period. | Day 12 | Yes | |
Secondary | A secondary endpoint is the parasitological cure 3, 6, 12, 24 months after completion of treatment. | 3, 6, 12, 24 months | No | |
Secondary | The secondary outcome measure will be the incidence rate of adverse events (all Grades combined) during the observation period (as compared to literature values for pentamidine). | Day 12 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01483170 -
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
|
Phase 1 | |
Terminated |
NCT00489658 -
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
|
Phase 2/Phase 3 | |
Completed |
NCT03087955 -
Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
|
Phase 2/Phase 3 | |
Completed |
NCT03025789 -
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
|
Phase 3 | |
Completed |
NCT02571062 -
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
|
Phase 1 | |
Terminated |
NCT00330148 -
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
|
Phase 3 | |
Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05645822 -
Screen and Treat Implementation for HAT Control
|
||
Completed |
NCT05947604 -
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
|
Phase 1 | |
Completed |
NCT01533961 -
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
|
Phase 1 | |
Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT00146627 -
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
|
Phase 3 |